NASDAQ:BWAY BrainsWay (BWAY) Stock Price, News & Analysis → Don’t make this retirement mistake (From Sasco Gold LLC) (Ad) Free BWAY Stock Alerts $6.56 -0.10 (-1.50%) (As of 11:22 AM ET) Add Compare Share Share Today's Range$6.55▼$6.6450-Day Range$4.74▼$7.0852-Week Range$2.01▼$7.61Volume7,863 shsAverage Volume107,852 shsMarket Capitalization$109.22 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get BrainsWay alerts: Email Address BrainsWay MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside95.2% Upside$13.00 Price TargetShort InterestHealthy0.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 15 Articles This WeekInsider TradingN/AProj. Earnings Growth350.00%From $0.02 to $0.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.35 out of 5 starsMedical Sector276th out of 904 stocksSurgical & Medical Instruments Industry36th out of 96 stocks 3.3 Analyst's Opinion Consensus RatingBrainsWay has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBrainsWay has only been the subject of 2 research reports in the past 90 days.Read more about BrainsWay's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.29% of the outstanding shares of BrainsWay have been sold short.Short Interest Ratio / Days to CoverBrainsWay has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BrainsWay has recently decreased by 24.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainsWay does not currently pay a dividend.Dividend GrowthBrainsWay does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BWAY. Previous Next 3.1 News and Social Media Coverage News SentimentBrainsWay has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for BrainsWay this week, compared to 1 article on an average week.Search Interest3 people have searched for BWAY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BrainsWay insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.11% of the stock of BrainsWay is held by institutions.Read more about BrainsWay's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BrainsWay are expected to grow by 350.00% in the coming year, from $0.02 to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BrainsWay is -73.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BrainsWay is -73.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBrainsWay has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BrainsWay's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About BrainsWay Stock (NASDAQ:BWAY)BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Read More BWAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BWAY Stock News HeadlinesJune 11 at 6:20 AM | investorplace.comSmall-Cap Standouts: 3 Stocks Destined to Rule Their IndustriesJune 11 at 6:20 AM | investorplace.comSmall-Cap Standouts: 3 Stocks Destined to Rule Their IndustriesJune 11 at 1:54 AM | americanbankingnews.comEquities Analysts Issue Forecasts for BrainsWay Ltd.'s FY2024 Earnings (NASDAQ:BWAY)June 10 at 7:30 AM | globenewswire.comBrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for DepressionJune 8 at 1:36 AM | americanbankingnews.comQ2 2024 Earnings Forecast for BrainsWay Ltd. Issued By HC Wainwright (NASDAQ:BWAY)June 6, 2024 | americanbankingnews.comBrainsWay (NASDAQ:BWAY) Receives "Buy" Rating from HC WainwrightJune 3, 2024 | globenewswire.comBrainsWay Receives Expanded FDA Labeling to Treat Late Life DepressionMay 9, 2024 | seekingalpha.comBrainsWay: Cash Flows Are UnderappreciatedMay 8, 2024 | markets.businessinsider.comBWAY Stock Earnings: BrainsWay Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comBrainsWay Reports First Quarter 2024 Financial Results and Operational HighlightsApril 24, 2024 | globenewswire.comBrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024April 19, 2024 | stockhouse.comBrainsWay Expands Deep TMS(TM) Access in Israel Following Significant Increase in Reimbursement RatesApril 8, 2024 | msn.comOutset Medical stock rallies 22% as BTIG starts coverage at buyApril 6, 2024 | stockhouse.comBrainsWay Announces Published Review Results Highlighting Potential of Deep TMS(TM) to Treat Parkinson's DiseaseApril 5, 2024 | uk.investing.comBrainsWay Announces Published Review Results Highlighting Potential of Deep ™S™ to Treat Parkinson's DiseaseApril 4, 2024 | finanznachrichten.deBrainsWay Announces Published Review Results Highlighting Potential of Deep TMS to Treat Parkinson's DiseaseApril 4, 2024 | globenewswire.comBrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's DiseaseMarch 31, 2024 | msn.comCompare with Sofwave Medical Ltd (SOFW)March 28, 2024 | finance.yahoo.comBrainsWay Announces Positive Results in Late-Life Depression Post-Marketing AnalysisMarch 18, 2024 | finance.yahoo.comBrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ SystemsMarch 18, 2024 | globenewswire.comBrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ SystemsMarch 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 11, 2024 | markets.businessinsider.comBuy Rating and Raised Price Target for Brainsway Reflecting Strong Financial Growth and Expansion PotentialMarch 8, 2024 | seekingalpha.comBrainsWay Ltd. (BWAY) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | msn.comBrainsway beats top-line and bottom-line estimates; initiates FY24 outlookSee More Headlines Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/11/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BWAY CUSIPN/A CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees134Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$15.00 Low Stock Price Target$11.00 Potential Upside/Downside+95.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E Ratio333.00 P/E GrowthN/ANet Income$-4,200,000.00 Net Margins-4.83% Pretax Margin-4.10% Return on Equity-3.98% Return on Assets-2.68% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.18 Sales & Book Value Annual Sales$31.78 million Price / Sales3.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book2.66Miscellaneous Outstanding Shares16,650,000Free Float13,488,000Market Cap$110.89 million OptionableNot Optionable Beta1.23 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Hadar Levy (Age 50)Chief Executive Officer Comp: $434kMr. Avner Hagai (Age 68)Founder & Director Comp: $43.65kProf. Abraham Zangen (Age 54)Co-Founder, Member of Scientific Advisory Board & Director Comp: $72.17kDr. Yiftach Roth Ph.D. (Age 53)Founder & Chief Scientific Officer Comp: $108kMr. Ido Marom (Age 48)Chief Financial Officer Mr. Menachem C. Klein Esq.VP, General Counsel & Corporate SecretaryDr. Aron TendlerChief Medical OfficerMore ExecutivesKey CompetitorsBeyond AirNASDAQ:XAIRAnika TherapeuticsNASDAQ:ANIKSight SciencesNASDAQ:SGHTOraSure TechnologiesNASDAQ:OSURNevroNYSE:NVROView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 11,273 shares on 5/20/2024Ownership: 0.068%Acadian Asset Management LLCBought 149,740 shares on 5/10/2024Ownership: 1.054%Essex Investment Management Co. LLCBought 88,593 shares on 5/3/2024Ownership: 1.952%Quadrature Capital LtdBought 10,761 shares on 3/25/2024Ownership: 0.065%View All Institutional Transactions BWAY Stock Analysis - Frequently Asked Questions Should I buy or sell BrainsWay stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BWAY shares. View BWAY analyst ratings or view top-rated stocks. What is BrainsWay's stock price target for 2024? 3 analysts have issued twelve-month price objectives for BrainsWay's shares. Their BWAY share price targets range from $11.00 to $15.00. On average, they predict the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price. View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts. How have BWAY shares performed in 2024? BrainsWay's stock was trading at $6.48 at the beginning of the year. Since then, BWAY stock has increased by 2.8% and is now trading at $6.66. View the best growth stocks for 2024 here. Are investors shorting BrainsWay? BrainsWay saw a decline in short interest in May. As of May 15th, there was short interest totaling 48,600 shares, a decline of 24.5% from the April 30th total of 64,400 shares. Based on an average trading volume of 83,400 shares, the days-to-cover ratio is presently 0.6 days. View BrainsWay's Short Interest. When is BrainsWay's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our BWAY earnings forecast. How were BrainsWay's earnings last quarter? BrainsWay Ltd. (NASDAQ:BWAY) posted its quarterly earnings data on Wednesday, May, 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.65 million. BrainsWay had a negative trailing twelve-month return on equity of 3.98% and a negative net margin of 4.83%. What guidance has BrainsWay issued on next quarter's earnings? BrainsWay updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $37.0 million-$40.0 million, compared to the consensus revenue estimate of $37.8 million. What other stocks do shareholders of BrainsWay own? Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET). When did BrainsWay IPO? BrainsWay (BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO. Who are BrainsWay's major shareholders? BrainsWay's stock is owned by a variety of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.95%), Acadian Asset Management LLC (1.05%) and Virtu Financial LLC (0.07%). How do I buy shares of BrainsWay? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BWAY) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BrainsWay With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
